Romatolojik Hastalıkların Nörolojik Manifestasyonları: Otoinflamatuar Hastalıklarda Nöroimmunolojik Mekanizmalar

Van Kempen TS, Wenink MH, Leijten EF, et al. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol. 2015 Aug;11(8):483-92. doi: 10.1038/nrrheum.2015.60. Epub 2015 May 12. PMID: 25963881.

Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007 Jan;14(1):10-22. doi: 10.1038/sj.cdd.4402038. Epub 2006 Sep 15. PMID: 16977329

Tartey S, Kanneganti TD. Inflammasomes in the pathophysiology of autoinflammatory syndromes. J Leukoc Biol. 2020 Mar;107(3):379-391. doi: 10.1002/JLB.3MIR0919-191R. Epub 2019 Oct 14. PMID: 31608507; PMCID: PMC7044027

Bulté D, Rigamonti C, Romano A, Mortellaro A. Inflammasomes: Mechanisms of Action and Involvement in Human Diseases. Cells. 2023 Jul 3;12(13):1766. doi: 10.3390/cells12131766. PMID: 37443800; PMCID: PMC10340308

Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014 May 22;157(5):1013-22. doi: 10.1016/j.cell.2014.04.007. PMID: 24855941

Aksentijevich I, Schnappauf O. Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases. Nat Rev Rheumatol. 2021 Jul;17(7):405-425. doi: 10.1038/s41584-021-00614-1. Epub 2021 May 25. PMID: 34035534.

Uccelli A, Gattorno M. Neurological manifestations in autoinflammatory diseases. Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):61-67. Epub 2018 May 3. PMID: 29742058

Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014 May 22;157(5):1013-22. doi: 10.1016/j.cell.2014.04.007. PMID: 24855941.

Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015 May;265(1):6-21. doi: 10.1111/imr.12296. PMID: 25879280; PMCID: PMC4400844

Goldbach-Mansky R, de Jesus AA. Classification of Genetically Defined Autoinflammatory Diseases. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 167–202

Levy R, Gérard L, Kuemmerle-Deschner J, et al; for PRINTO and Eurofever. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015 Nov;74(11):2043-9. doi: 10.1136/annrheumdis-2013-204991. Epub 2014 Jul 18. PMID: 25038238.

Parker T, Keddie S, Kidd D, et al. Neurology of the cryopyrin-associated periodic fever syndrome. Eur J Neurol. 2016 Jul;23(7):1145-51. doi: 10.1111/ene.12965. Epub 2016 Mar 2. PMID: 26931528.

Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2017 Jun;76(6):942-947. doi: 10.1136/annrheumdis-2016-209686. Epub 2016 Oct 4. PMID: 27707729.

Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The Pyrin Inflammasome in Health and Disease. Front Immunol. 2019 Aug 7;10:1745. doi: 10.3389/fimmu.2019.01745. PMID: 31456795; PMCID: PMC6698799

Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002 Dec;46(12):3340-8. doi: 10.1002/art.10688. PMID: 12483741; PMCID: PMC4556432.

Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007 Apr;56(4):1273-1285. doi: 10.1002/art.22491. PMID: 17393462; PMCID: PMC4321998

Barron K, Kastner DL. Periodic Fever Syndromes and Other Inherited Autoinflammatory Diseases. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn L, Mellins E, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8th ed. Philadelphia, PA: Elsevier; 2021. p. 525–42.

Saatçi U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997 Aug;156(8):619-23. doi: 10.1007/s004310050677. PMID: 9266193.

Özen S. Update on the epidemiology and disease outcome of Familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):254-260. doi: 10.1016/j.berh.2018.09.003. Epub 2018 Sep 29. PMID: 30527430.

Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4. PMID: 19193696.

Gattorno M, Hofer M, Federici S, et al; Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO). Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019 Aug;78(8):1025-1032. doi: 10.1136/annrheumdis-2019-215048. Epub 2019 Apr 24. PMID: 31018962.

Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005 Jan;84(1):1-11. doi: 10.1097/01.md.0000152370.84628.0c. PMID: 15643295.

Salehzadeh F, Azami A, Motezarre M, et al. Neurological Manifestations in Familial Mediterranean Fever: a Genotype-Phenotype Correlation Study. Open Access Rheumatol. 2020 Jan 15;12:15-19. doi: 10.2147/OARRR.S238649. PMID: 32021503; PMCID: PMC6970254.

Kalyoncu U, Eker A, Oguz KK, et al. Familial Mediterranean fever and central nervous system involvement: a case series. Medicine (Baltimore). 2010 Mar;89(2):75-84. doi: 10.1097/MD.0b013e3181d5dca7. PMID: 20517179.

Feld O, Yahalom G, Livneh A. Neurologic and other systemic manifestations in FMF: published and own experience. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):119-33. doi: 10.1016/j.berh.2012.01.004. PMID: 22424198.

Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. doi: 10.1542/peds.2006-1434. Epub 2007 Jan 22. PMID: 17242135.

Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. doi: 10.1136/annrheumdis-2015-208690. Epub 2016 Jan 22. PMID: 26802180.

Mulders-Manders CM, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? Semin Immunopathol. 2015 Jul;37(4):371-6. doi: 10.1007/s00281-015-0492-6. Epub 2015 May 20. PMID: 25990874; PMCID: PMC4491100.

Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006 Apr 26;1:13. doi: 10.1186/1750-1172-1-13. PMID: 16722536; PMCID: PMC1475558.

Brennenstuhl H, Nashawi M, Schröter J, et al; Unified Registry for Inherited Metabolic Disorders (U-IMD) Consortium and the European Registry for Hereditary Metabolic Disorders (MetabERN). Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria. J Inherit Metab Dis. 2021 Sep;44(5):1272-1287. doi: 10.1002/jimd.12412. Epub 2021 Jun 28. PMID: 34145613.

Van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013 Jun;147(3):197-206. doi: 10.1016/j.clim.2012.09.011. Epub 2012 Oct 4. PMID: 23110805.

ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24. PMID: 26109736.

Magnotti F, Vitale A, Rigante D, et al. The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):141-9. Epub 2013 Jul 24. PMID: 23899820.

Rigante D, Lopalco G, Vitale A, et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol. 2014 Sep;33(9):1197-207. doi: 10.1007/s10067-014-2722-z. Epub 2014 Jun 17. PMID: 24935411.

Lachmann HJ, Papa R, Gerhold K, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014 Dec;73(12):2160-7. doi: 10.1136/annrheumdis-2013-204184. Epub 2013 Aug 21. PMID: 23965844; PMCID: PMC4251160.

Caminero A, Comabella M, Montalban X. Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. Clin Exp Immunol. 2011 Dec;166(3):338-45. doi: 10.1111/j.1365-2249.2011.04484.x. PMID: 22059991; PMCID: PMC3232381.

Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med. 2016 Nov 14;213(12):2527-2538. doi: 10.1084/jem.20161596. Epub 2016 Nov 7. PMID: 27821552; PMCID: PMC5110029.

Davidson S, Steiner A, Harapas CR, Masters SL. An Update on Autoinflammatory Diseases: Interferonopathies. Curr Rheumatol Rep. 2018 May 30;20(7):38. doi: 10.1007/s11926-018-0748-y. PMID: 29846818.

Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010 Sep 27;207(10):2053-63. doi: 10.1084/jem.20101664. Epub 2010 Sep 13. PMID: 20837696; PMCID: PMC2947062.

Lee-Kirsch MA, Wolf C, Kretschmer S, Roers A. Type I interferonopathies--an expanding disease spectrum of immunodysregulation. Semin Immunopathol. 2015 Jul;37(4):349-57. doi: 10.1007/s00281-015-0500-x. Epub 2015 May 22. PMID: 25998914.

Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol. 2022 Aug;22(8):471-483. doi: 10.1038/s41577-021-00633-9. Epub 2021 Oct 20. PMID: 34671122; PMCID: PMC8527296.

Wilms AE, de Boer I, Terwindt GM. Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives. Cereb Circ Cogn Behav. 2022 Feb 14;3:100046. doi: 10.1016/j.cccb.2022.100046. PMID: 36324396; PMCID: PMC9616387.

Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022 May;81(5):601-613. doi: 10.1136/annrheumdis-2021-221814. Epub 2022 Jan 27. PMID: 35086813; PMCID: PMC9036471.

Pelzer N, Hoogeveen ES, Haan J, et al. Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. J Intern Med. 2019 Mar;285(3):317-332. doi: 10.1111/joim.12848. Epub 2018 Nov 8. PMID: 30411414.

Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J. 2014 Aug 6;12:33. doi: 10.1186/1546-0096-12-33. PMID: 25136265; PMCID: PMC4136643.

Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012 Nov;12(1):44-51. doi: 10.1016/j.autrev.2012.07.028. Epub 2012 Aug 2. PMID: 22884558.

Negroni A, Pierdomenico M, Cucchiara S, Stronati L. NOD2 and inflammation: current insights. J Inflamm Res. 2018 Feb 12;11:49-60. doi: 10.2147/JIR.S137606. PMID: 29483781; PMCID: PMC5813767.

Rosé CD, Aróstegui JI, Martin TM, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum. 2009 Jun;60(6):1797-803. doi: 10.1002/art.24533. PMID: 19479837; PMCID: PMC2768567.

Emaminia A, Nabavi M, Mousavi Nasab M, Kashef S. Central nervous system involvement in Blau syndrome: a new feature of the syndrome? J Rheumatol. 2007 Dec;34(12):2504-5. Erratum in: J Rheumatol. 2008 May;35(5):943. Emami Nia, Abbas [corrected to Emaminia, Abbas]. PMID: 18061972.

Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018 Jul;38(5):569-578. doi: 10.1007/s10875-018-0525-8. Epub 2018 Jun 27. PMID: 29951947; PMCID: PMC6061100.

Şahin, N., Cicek, S., Paç Kısaarslan, A., et al (2021). Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis. TURKISH JOURNAL OF PEDIATRICS , no.2, 323-328.

Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014 Jan;35(1):22-31. doi: 10.1016/j.it.2013.10.005. Epub 2013 Nov 15. PMID: 24246475.

Yu MP, Xu XS, Zhou Q, et al. Haploinsufficiency of A20 (HA20): updates on the genetics, phenotype, pathogenesis and treatment. World J Pediatr. 2020 Dec;16(6):575-584. doi: 10.1007/s12519-019-00288-6. Epub 2019 Oct 5. PMID: 31587140.

Aeschlimann FA, Batu ED, Canna SW, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018 May;77(5):728-735. doi: 10.1136/annrheumdis-2017-212403. Epub 2018 Jan 9. PMID: 29317407.

Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20. doi: 10.1056/NEJMoa1307361. Epub 2014 Feb 19. PMID: 24552284; PMCID: PMC4193683.

Barron KS, Aksentijevich I, Deuitch NT, et al. The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort. Front Immunol. 2022 Jan 10;12:811473. doi: 10.3389/fimmu.2021.811473. PMID: 35095905; PMCID: PMC8790931.

Carmona-Rivera C, Khaznadar SS, Shwin KW, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019 Jul 25;134(4):395-406. doi: 10.1182/blood.2018892752. Epub 2019 Apr 23. PMID: 31015188; PMCID: PMC6659253.

Zavialov AV, Gracia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010 Aug;88(2):279-90. doi: 10.1189/jlb.1109764. Epub 2010 May 7. PMID: 20453107.

Belot A, Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014 Sep 24;12:44. doi: 10.1186/1546-0096-12-44. PMID: 25278816; PMCID: PMC4181355.

Özen S, Batu ED, Taşkıran EZ, et al. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. J Rheumatol. 2020 Jan;47(1):117-125. doi: 10.3899/jrheum.181384. Epub 2019 May 1. PMID: 31043544.

Navon Elkan P, Pierce SB, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014 Mar 6;370(10):921-31. doi: 10.1056/NEJMoa1307362. Epub 2014 Feb 19. PMID: 24552285.

Moens L, Hershfield M, Arts K, et al. Human adenosine deaminase 2 deficiency: A multi-faceted inborn error of immunity. Immunol Rev. 2019 Jan;287(1):62-72. doi: 10.1111/imr.12722. PMID: 30565235.

Sahin S, Adrovic A, Kasapcopur O. A monogenic autoinflammatory disease with fatal vasculitis: deficiency of adenosine deaminase 2. Curr Opin Rheumatol. 2020;32(1):3–14

Bulut E, Erden A, Karadag O, et al. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J Neuroradiol. 2019 May;46(3):193-198. doi: 10.1016/j.neurad.2018.05.002. Epub 2018 Jun 18. PMID: 29913178.

Huang Z, Li T, Nigrovic PA, Lee PY. Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. Clin Immunol. 2020 Jun;215:108411. doi: 10.1016/j.clim.2020.108411. Epub 2020 Apr 7. PMID: 32276138; PMCID: PMC7387119.

Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20. doi: 10.1056/NEJMoa1307361. Epub 2014 Feb 19. PMID: 24552284; PMCID: PMC4193683.

Pizzatto R, Resende LL, Lobo CFT, et al. Arteriopathy in pediatric stroke: an underestimated clinical entity. Arq Neuropsiquiatr. 2021 Apr;79(4):321-333. doi: 10.1590/0004-282X-ANP-2020-0105. PMID: 34133513; PMCID: PMC9231440

Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715. PMID: 23045170

Koné-Paut I, Shahram F, Darce-Bello M, et al; PEDBD group. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016 Jun;75(6):958-64. doi: 10.1136/annrheumdis-2015-208491. Epub 2015 Dec 23. PMID: 26698843

Uluduz D, Kürtüncü M, Yapıcı Z, et al. Clinical characteristics of pediatric-onset neuro-Behçet disease. Neurology. 2011 Nov 22;77(21):1900-5. doi: 10.1212/WNL.0b013e318238edeb. Epub 2011 Nov 9. PMID: 22076549

Motomura S, Tabira T, Kuroiwa Y. A clinical comparative study of multiple sclerosis and neuro-Behçet's syndrome. J Neurol Neurosurg Psychiatry. 1980 Mar;43(3):210-3. doi: 10.1136/jnnp.43.3.210. PMID: 7373318; PMCID: PMC490512.

Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol. 2014 Sep;261(9):1662-76. doi: 10.1007/s00415-013-7209-3. Epub 2013 Dec 24. PMID: 24366648; PMCID: PMC4155170.